Found: 83
Select item for more details and to access through your institution.
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 1, p. 47, doi. 10.1007/s10637-016-0391-2
- By:
- Publication type:
- Article
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5
- By:
- Publication type:
- Article
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1958, doi. 10.1007/s10637-011-9753-y
- By:
- Publication type:
- Article
Oral health in oncology: impact of immunotherapy.
- Published in:
- 2015
- By:
- Publication type:
- Letter
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 9, p. 1033, doi. 10.1007/s00262-005-0090-x
- By:
- Publication type:
- Article
Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2002, v. 51, n. 5, p. 263, doi. 10.1007/s00262-002-0281-7
- By:
- Publication type:
- Article
CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
- Published in:
- Nature Communications, 2016, v. 7, n. 1, p. 10582, doi. 10.1038/ncomms10582
- By:
- Publication type:
- Article
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 311, n. 23, p. 2397, doi. 10.1001/jama.2014.6096
- By:
- Publication type:
- Article
B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma.
- Published in:
- Current Oncology Reports, 2010, v. 12, n. 3, p. 146, doi. 10.1007/s11912-010-0095-2
- By:
- Publication type:
- Article
Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.
- Published in:
- Current Oncology Reports, 2009, v. 11, n. 5, p. 405, doi. 10.1007/s11912-009-0054-y
- By:
- Publication type:
- Article
Kidney Cancer: Recent Advances in Diagnosis and Management.
- Published in:
- AUANews, 2008, v. 13, p. 7
- By:
- Publication type:
- Article
Leptomeningeal metastases: the future is now.
- Published in:
- Journal of Neuro-Oncology, 2022, v. 156, n. 3, p. 443, doi. 10.1007/s11060-021-03924-2
- By:
- Publication type:
- Article
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
- Published in:
- Nature, 2011, v. 480, n. 7377, p. 387, doi. 10.1038/nature10662
- By:
- Publication type:
- Article
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
- Published in:
- Nature, 2010, v. 468, n. 7326, p. 973, doi. 10.1038/nature09626
- By:
- Publication type:
- Article
CORRESPONDENCE.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Sunlight and Reduced Risk of Cancer: Is The Real Story Vitamin D?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 3, p. 161, doi. 10.1093/jnci/dji047
- By:
- Publication type:
- Article
Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.
- Published in:
- 2019
- By:
- Publication type:
- letter
Immune Checkpoint Inhibitor Toxicity in 2018.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Spindle Cell Squamous Carcinoma During BRAF Inhibitor Therapy for Advanced Melanoma: An Aggressive Secondary Neoplasm of Undetermined Biologic Potential.
- Published in:
- JAMA Dermatology, 2014, v. 150, n. 5, p. 575, doi. 10.1001/jamadermatol.2013.7784
- By:
- Publication type:
- Article
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00200
- By:
- Publication type:
- Article
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. 1, doi. 10.1038/s41467-018-08123-8
- By:
- Publication type:
- Article
Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
- Published in:
- Current Oncology Reports, 2016, v. 18, n. 1, p. 1, doi. 10.1007/s11912-015-0485-6
- By:
- Publication type:
- Article
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production.
- Published in:
- British Journal of Haematology, 2000, v. 111, n. 1, p. 104, doi. 10.1046/j.1365-2141.2000.02314.x
- By:
- Publication type:
- Article
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 3, p. 439, doi. 10.1007/s00432-016-2318-x
- By:
- Publication type:
- Article
Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 731, doi. 10.1002/onco.13795
- By:
- Publication type:
- Article
Hybrid Capture‐Based Genomic Profiling Identifies BRAF V600 and Non‐V600 Alterations in Melanoma Samples Negative by Prior Testing.
- Published in:
- Oncologist, 2019, v. 24, n. 5, p. 657, doi. 10.1634/theoncologist.2018-0271
- By:
- Publication type:
- Article
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 648, doi. 10.1634/theoncologist.2014-0468
- By:
- Publication type:
- Article
Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel.
- Published in:
- Oncologist, 2014, v. 19, n. 6, p. 616, doi. 10.1634/theoncologist.2014-0011
- By:
- Publication type:
- Article
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 8, p. 1904, doi. 10.1002/cam4.1140
- By:
- Publication type:
- Article
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials.
- Published in:
- PLoS ONE, 2012, v. 7, n. 4, p. 1, doi. 10.1371/journal.pone.0035309
- By:
- Publication type:
- Article
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Melanoma: What do all the mutations mean?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
- Published in:
- BJU International, 2005, v. 96, n. 3, p. 286, doi. 10.1111/j.1464-410X.2005.05616.x
- By:
- Publication type:
- Article
Cancer Immunotherapies: Are They as Effective in the Elderly?
- Published in:
- Drugs & Aging, 2017, v. 34, n. 8, p. 567, doi. 10.1007/s40266-017-0479-1
- By:
- Publication type:
- Article
Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
- Published in:
- American Journal of Clinical Dermatology, 2018, v. 19, n. 5, p. 657, doi. 10.1007/s40257-018-0359-4
- By:
- Publication type:
- Article
Endocrine side effects of immune checkpoint inhibitors.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1157805
- By:
- Publication type:
- Article
The Human Vaccines Project: A roadmap for cancer vaccine development.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 334, p. 1, doi. 10.1126/scitranslmed.aaf0685
- By:
- Publication type:
- Article
Nivolumab in melanoma: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2015, v. 7, n. 2, p. 97, doi. 10.1177/1758834014567469
- By:
- Publication type:
- Article
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00896-0
- By:
- Publication type:
- Article
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2020, v. 33, n. 3, p. 390, doi. 10.1111/pcmr.12847
- By:
- Publication type:
- Article
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
- Published in:
- Pigment Cell & Melanoma Research, 2019, v. 32, n. 3, p. 458, doi. 10.1111/pcmr.12771
- By:
- Publication type:
- Article
BRAF and MEK inhibitor therapy eliminates Nestin‐expressing melanoma cells in human tumors.
- Published in:
- Pigment Cell & Melanoma Research, 2018, v. 31, n. 6, p. 708, doi. 10.1111/pcmr.12712
- By:
- Publication type:
- Article
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
- Published in:
- Pigment Cell & Melanoma Research, 2018, v. 31, n. 3, p. 432, doi. 10.1111/pcmr.12674
- By:
- Publication type:
- Article
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1 AX driver mutations in melanoma and across the cancer spectrum.
- Published in:
- Pigment Cell & Melanoma Research, 2016, v. 29, n. 4, p. 470, doi. 10.1111/pcmr.12482
- By:
- Publication type:
- Article